Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
-
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
-
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights
-
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
-
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
-
The National Association of RV Parks and Campgrounds named seven Jellystone Park locations as finalists for Park of the Year.